Brian Stover, MD

Pediatric Hematologist/Oncologist (Child Cancer Specialist)

Active clinical trials

Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)

This phase III trial studies using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype.…

Investigator: Brian Stover
Status: Accepting Candidates
Ages: N/A - 30 Years
Sexes: All

Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard…

Investigator: Brian Stover
Status: Accepting Candidates
Ages: N/A - 39 Years
Sexes: Female

A Study With DAY101 as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell H

This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after…

Investigator: Brian Stover
Status: Accepting Candidates
Ages: 180 Days - 22 Years
Sexes: All